Purdue Pharma

About: Purdue Pharma is a company organization based out in Pickering, Ontario, Canada. It is known for research contribution in the topics: Buprenorphine & Chronic pain. The organization has 622 authors who have published 691 publications receiving 31545 citations. The organization is also known as: Purdue Pharmaceuticals L.P..

Substituted pyridines useful for treating pain

Abstract: A compound of Formula: (I) or a pharmaceutically acceptable derivative thereof, where Ar1, Ar2, X, R3, and m are as disclosed herein. Compounds of Formulae (I)-(V) and pharmaceutically acceptable derivatives thereof; compositions comprising an effective amount of a compound of Formulae (I)-(V) or a pharmaceutically acceptable derivative thereof; and methods for treating or preventing pain, UI, an ulcer, IBD, or IBS in an animal comprising administering to an animal in need thereof an effective amount of a compound of Formulae (I)-(V) or a pharmaceutically acceptable derivative thereof are disclosed herein.

Dispenser for transdermal devices

Abstract: A dispenser places transdermal devices and packaged transdermal devices in an electrically charged state. The dispenser is particularly suitable for transdermal devices that include electrically actuatable components, such as transdermal, drug-delivery patches that include microporator circuitry. A controller can be operatively coupled to a power circuit of the dispenser to control the times that transdermal devices can be charged, thereby providing a measure of control over use and misuse of the transdermal devices to be dispensed.

Quinazolin-4(3h)-one-type piperidine compounds and uses thereof

Abstract: The present disclosure relates to Quinazolin-4(3H)-one-Type Piperidine Compounds, such as those of Formule (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Q, Y1, Z, A, B, E, and a are as defined herein; compositions comprising an effective amount of a Quinazolin-4(3H)-one-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Quinazolin-4(3 H)-one-Type Piperidine Compound.

Future Needs in Issue Resolution of Problems That Arise in Drug Development

Abstract: Safety pharmacology seeks to validate and refine methods for use in preclinical detection of new chemical entity adverse effect liability It does so in accordance with the scientific method and seeks to organize the strategy of implementation of methods according to regulatory guidance documents The discipline is in rapid evolution and its coverage is certain to expand to provide better guidance for the safety evaluation of more physiological systems This effort is critical as the pursuit of drug development is costly and has high drug failure rates Strategies and nonclinical methods and models are essential to prevent the development of adverse events during clinical trials Technologies involved in the acquisition and analysis of safety pharmacology data are rapidly evolving and the safety pharmacologist often benefits from an in-depth understanding of such underlying technologies and associated methodologies This gives a broad perspective to data interpretation and a better armamentarium with which to address adverse events related to the administration of the test article Establishing the safety profile of a drug is a key responsibility in the conduct of safety pharmacology studies To formulate a clear perspective, no effort should be spared to achieve high assay sensitivity and high predictivity of adverse event development in safety pharmacology studies An emphasis must be placed on the development of translatable nonclinical safety pharmacology methods that identify and characterize not only cardiovascular but also related core battery (ie, central nervous system and respiratory systems) study risks If adverse events are observed in a safety pharmacology study, scientists need to develop a mitigation strategy that allows for either progression of the lead compound into further nonclinical development and eventual clinical evaluation or sufficient insight into why the compound (or program) should be recommended for termination The future needs in issue resolution of problems that arise in drug development require highly skilled drug safety scientists with a broad understanding of essential biological principles, an awareness of novel methods and models and their application to discerning adverse event development and subsequent mitigation, and insight into clinical translational relevance